Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …

Background First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide)
showed a significant improvement in overall survival versus platinum–…

Aim: To investigate potential association between administration of corticosteroids, antibiotics,
probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins …

BACKGROUND: We evaluated the performance of a galactomannan (GM) assay in
bronchoalveolar lavage (BAL) fluid compared to serum samples for the diagnosis of invasive …

Purpose: This randomized, multicenter, phase III trial was conducted to compare the tolerability
of gemcitabine plus cisplatin (GP) vs. gemcitabine plus carboplatin (GC) in chemonaive …

Patients with lung cancer experience elevated risk of venous thromboembolism. Cancer
patients with thrombosis have a shorter life expectancy and the occurrence of VTE worsens the …

Aim: To investigate potential associations between clinical and standard peripheral blood
biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated …

Background: Malnutrition in cancer patients may be associated with poor tolerance of
chemotherapy and lower response rate after oncological treatment. Methods: Nutritional Risk …

Background. The concurrence of obstructive sleep apnea (OSA) and chronic obstructive
pulmonary disease (COPD) is generally identified as an overlap syndrome. Only limited …

Background: Identification of serum and bronchoalveolar lavage fluid (BALF) biomarkers
may facilitate diagnosis and prognostication in various lung disorders. Objective: Serum and …